Abstract
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation/expansion of a clonal population of small mature B lymphocytes in blood, bone marrow, and lymphoid organs. Although initial genetic events are considered primarily responsible for the first step(s) of neoplastic transformation, the development and progression of the CLL clone are thought to be affected by various micro-environmental signals that regulate proliferation and survival of malignant B cells. In the present review, we focus on specific interactions of CLL cells with the microenvironmental component, as they occur through the usage by CLL cells of specific molecular structures whose expression has been associated with prognosis, including: i) interactions of CLL cells via the surface BCR and dependent on specific molecular features of the BCR itself and/or the presence of the BCR-associated molecule ZAP- 70; ii) non-BCR-dependent proliferative and/or pro-survival interactions of CLL cells by CD49d and CD38. An overview of the putative drugs that could be employed to target specific molecules involved in CLL cells/tumor microenvironment interactions is also proposed in the closing chapter of the review.
Keywords: Chronic lymphocytic leukemia, microenvironment, therapy, B lymphocytes, neoplastic transformation, BCR, CD49d, CD38, putative drugs, lymphoid organs
Current Pharmaceutical Design
Title:Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Volume: 18 Issue: 23
Author(s): Michele Dal Bo, Riccardo Bomben, Antonella Zucchetto, Giovanni Del Poeta, Gianluca Gaidano, Silvia Deaglio, Dimitar G. Efremov and Valter Gattei
Affiliation:
Keywords: Chronic lymphocytic leukemia, microenvironment, therapy, B lymphocytes, neoplastic transformation, BCR, CD49d, CD38, putative drugs, lymphoid organs
Abstract: Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation/expansion of a clonal population of small mature B lymphocytes in blood, bone marrow, and lymphoid organs. Although initial genetic events are considered primarily responsible for the first step(s) of neoplastic transformation, the development and progression of the CLL clone are thought to be affected by various micro-environmental signals that regulate proliferation and survival of malignant B cells. In the present review, we focus on specific interactions of CLL cells with the microenvironmental component, as they occur through the usage by CLL cells of specific molecular structures whose expression has been associated with prognosis, including: i) interactions of CLL cells via the surface BCR and dependent on specific molecular features of the BCR itself and/or the presence of the BCR-associated molecule ZAP- 70; ii) non-BCR-dependent proliferative and/or pro-survival interactions of CLL cells by CD49d and CD38. An overview of the putative drugs that could be employed to target specific molecules involved in CLL cells/tumor microenvironment interactions is also proposed in the closing chapter of the review.
Export Options
About this article
Cite this article as:
Dal Bo Michele, Bomben Riccardo, Zucchetto Antonella, Del Poeta Giovanni, Gaidano Gianluca, Deaglio Silvia, G. Efremov Dimitar and Gattei Valter, Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy, Current Pharmaceutical Design 2012; 18 (23) . https://dx.doi.org/10.2174/138161212801227078
DOI https://dx.doi.org/10.2174/138161212801227078 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Gender Disparity in Pediatric Diseases
Current Molecular Medicine Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia
Current Cancer Drug Targets MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient
Current Cancer Therapy Reviews Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Versatile and Valuable Utilization of Amidohydrolase L-glutaminase in Pharma and Food industries: A Review
Current Drug Metabolism The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Breast Cancer, a Stem Cell Disease
Current Stem Cell Research & Therapy Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Folate-conjugated Chitosan-poly(ethylenimine) Copolymer As An Efficient and Safe Vector For Gene Delivery in Cancer Cells
Current Gene Therapy A Comprehensive Review on Perfusion Method Development for Bone Marrow Collection and Stem Cell Transplantation
Current Stem Cell Research & Therapy Characteristic Alterations of Nuclear Structure and Chromatin Organisation of Cancer Cells Addressed by Proteome Analysis**
Current Proteomics